329.83 USD
+0.09 (+0.03%)
329.83 USD
0 (0%)
Overall KRTX gets a fundamental rating of 3 out of 10. We evaluated KRTX against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KRTX as it has an excellent financial health rating, but there are worries on the profitability. KRTX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- KRTX had negative earnings in the past year.
- KRTX had a negative operating cash flow in the past year.
- In the past 5 years KRTX always reported negative net income.
- KRTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -32.46%, KRTX is in the better half of the industry, outperforming 69.32% of the companies in the same industry.
- KRTX has a Return On Equity of -34.58%. This is in the better half of the industry: KRTX outperforms 78.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.46% | ||
| ROE | -34.58% | ||
| ROIC | N/A |
ROA(3y)-27.82%
ROA(5y)-22.87%
ROE(3y)-29.25%
ROE(5y)-23.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for KRTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- KRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, KRTX has more shares outstanding
- There is no outstanding debt for KRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- KRTX has an Altman-Z score of 90.95. This indicates that KRTX is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of KRTX (90.95) is better than 98.81% of its industry peers.
- There is no outstanding debt for KRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 90.95 |
ROIC/WACCN/A
WACC8.97%
2.3 Liquidity
- KRTX has a Current Ratio of 19.31. This indicates that KRTX is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 19.31, KRTX belongs to the best of the industry, outperforming 93.56% of the companies in the same industry.
- A Quick Ratio of 19.31 indicates that KRTX has no problem at all paying its short term obligations.
- KRTX has a Quick ratio of 19.31. This is amongst the best in the industry. KRTX outperforms 93.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.31 | ||
| Quick Ratio | 19.31 |
3. Growth
3.1 Past
- The earnings per share for KRTX have decreased strongly by -34.42% in the last year.
- The Revenue for KRTX has decreased by -93.89% in the past year. This is quite bad
EPS 1Y (TTM)-34.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.59%
Revenue 1Y (TTM)-93.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
- KRTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.97% yearly.
- Based on estimates for the next years, KRTX will show a very strong growth in Revenue. The Revenue will grow by 331.85% on average per year.
EPS Next Y-5.2%
EPS Next 2Y13.86%
EPS Next 3Y27.79%
EPS Next 5Y32.97%
Revenue Next Year1701.02%
Revenue Next 2Y1192.99%
Revenue Next 3Y680.54%
Revenue Next 5Y331.85%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- KRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KRTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as KRTX's earnings are expected to grow with 27.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.86%
EPS Next 3Y27.79%
5. Dividend
5.1 Amount
- KRTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KARUNA THERAPEUTICS INC / KRTX FAQ
What is the ChartMill fundamental rating of KARUNA THERAPEUTICS INC (KRTX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to KRTX.
Can you provide the valuation status for KARUNA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 1 / 10 to KARUNA THERAPEUTICS INC (KRTX). This can be considered as Overvalued.
Can you provide the profitability details for KARUNA THERAPEUTICS INC?
KARUNA THERAPEUTICS INC (KRTX) has a profitability rating of 1 / 10.
What is the earnings growth outlook for KARUNA THERAPEUTICS INC?
The Earnings per Share (EPS) of KARUNA THERAPEUTICS INC (KRTX) is expected to decline by -5.2% in the next year.